Compare
Zentalis Pharmaceuticals, Inc. vs Abbott Laboratories vs TherapeuticsMD, Inc. vs Nature's Sunshine Products Inc
| Latest fiscal year | Zentalis Pharmaceuticals, Inc. ZNTL | Abbott Laboratories ABT | TherapeuticsMD, Inc. TXMD | Nature's Sunshine Products Inc NATR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $44.33B | $3.02M | $480.14M |
| Revenue growth (YoY) | -100.0% | +5.7% | +71.6% | +5.7% |
| Gross margin | n/a | 56.4% (computed) | n/a | 72.4% |
| Operating margin | n/a | 18.2% | -145.3% | 5.2% |
| Net margin | n/a | 14.7% | -18.8% | 4.3% |
| Net income | -$137.06M | $6.52B | -$569.0K | $20.45M |
| EPS (Diluted) | -$1.91 | $3.72 | -$0.05 | $1.06 |
| Operating cash flow | -$125.25M | $9.57B | $2.45M | $35.32M |
| Free cash flow | -$125.25M | $7.39B | n/a | $28.84M |
| Cash & equivalents | $35.99M | $8.52B | n/a | $93.89M |
| Total assets | $288.97M | $86.71B | $37.66M | $261.15M |
| Total liabilities | $72.76M | n/a | $10.78M | $99.59M |
| Shareholders' equity | $216.20M | $52.13B | $26.88M | $161.55M |
| Return on year-end equity | -63.4% | 12.5% | -2.1% | 12.7% |
| Shares outstanding | 69.09M | n/a | 11.57M | 17.51M |
Revenue, most recent five fiscal years
| Fiscal year | Zentalis Pharmaceuticals, Inc. | Abbott Laboratories | TherapeuticsMD, Inc. | Nature's Sunshine Products Inc |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $44.33B Ended 2025-12-31 | $3.02M Ended 2025-12-31 | $480.14M Ended 2025-12-31 |
| 1 year earlier | $67.42M Ended 2024-12-31 | $41.95B Ended 2024-12-31 | $1.76M Ended 2024-12-31 | $454.36M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $40.11B Ended 2023-12-31 | $1.30M Ended 2023-12-31 | $445.32M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $43.65B Ended 2022-12-31 | $69.96M Ended 2022-12-31 | $421.91M Ended 2022-12-31 |
| 4 years earlier | n/a | $43.08B Ended 2021-12-31 | $2.57M Ended 2021-12-31 | $444.08M Ended 2021-12-31 |